---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-024413"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:39:41.443460+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments

## Summary
- Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.
- Purchase price of $300M paid in full at closing on June 27, 2025.
- Purchaser's annual cap equals 60% of Bayer royalties on first $500M of net sales; hard cap at 145% of purchase price.
- Company granted security interest in assets related to purchased royalty payment; change of control triggers option to assume or pay adjusted amount.

## SEC filing metadata
- accession: 0001140361-25-024413
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/0001140361-25-024413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/ef20051467_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-024413
- JSON: https://secwatch.observer/filing/0001140361-25-024413.json
- Plain text: https://secwatch.observer/filing/0001140361-25-024413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.